Compare Vanguard Mega Cap Growth ETF (MGK) vs Merck & Co., Inc. (MRK) Price & Performance

Vanguard Mega Cap Growth ETFTrade

Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Vanguard Mega Cap Growth ETF vs Merck & Co., Inc. — how do they compare? Vanguard Mega Cap Growth ETF trades at $90.27, while Merck & Co., Inc. trades at $132.87 (market cap $321.77B). The key difference: Merck & Co., Inc. pays a 2.61% dividend while Vanguard Mega Cap Growth ETF pays none, and Merck & Co., Inc. is trading nearer its 52-week high, Vanguard Mega Cap Growth ETF nearer its low. Which is the better fit depends on your goals.

	MGK	MRK
Sector	Broad Market / Factor	Health
52-Week High	$92.06	$131.84
52-Week Low	$70.70	$77.60
Market Cap	—	$321.77B
Enterprise Value	—	$368.53B
Dividend Yield	—	2.61%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vanguard Mega Cap Growth ETF

No Aura AI signal available yet.

Merck & Co., Inc.

Merck & Co. (MRK) trades at $133.64, up 2.09% today, with a bullish technical signal from moving averages and strong institutional buying interest. The company reported solid earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, and net income was $18.25B, though the P/E ratio of 104.34 suggests high valuation expectations. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.

Outlook: MRK's growth is supported by strategic acquisitions and a dominant oncology franchise, but risks include high valuation multiples and competitive pressures. The consensus price target of $140.36 implies modest upside, with 68% of analysts rating it a Buy. Investors should monitor execution on the Terns integration and Q3 earnings results for catalysts.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MGK

View details →

MRK

Merck reports 5% revenue growth in Q2 2026, boosted by KEYTRUDA and pipeline drugs, with positive analyst outlook.Danny Green · 5 hours agoBullish Revolution Medicines hits $44B market cap with breakthrough RAS cancer drugs, attracting big pharma interest.24/7 Wall Street · 8 hours agoBullish Bio-Techne reports flat FY2026 revenue, EPS rise, and confirms $11.3B acquisition by Merck KGaA.PRNewsWire · 10 hours agoBullish View details →

About Vanguard Mega Cap Growth ETF

MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.